tumor-specific adenovirus + flare-specific CAR T cells

**Tumor-specific adenovirus + flare-specific CAR T cells** is an investigational combination therapy designed to enhance CAR T cell efficacy against solid tumors. The **tumor-specific adenovirus**, an oncolytic virus engineered for selective replication in tumor cells (often under tumor-specific promoters like Ki67), lyses cancer cells, remodels the immunosuppressive tumor microenvironment (TME), secretes chemokines (e.g., CCL5) and cytokines (e.g., IL-12, IFN-γ) to recruit and activate immune cells, and boosts CAR T infiltration and persistence. **Flare-specific CAR T cells** are chimeric antigen receptor T cells engineered to target a tumor antigen upregulated or "flared" post-adenovirus infection, enabling precise tumor recognition and cytotoxicity. This synergy overcomes CAR T limitations in solid tumors, achieving complete regressions in preclinical xenograft models of renal, prostate, and pancreatic cancers, with induced long-term antitumor memory.[1]